Implications of bone metastases and the benefits of bone-targeted therapy.
about
Biology of bone metastases.Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant diseaseCryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases.Emerging therapies in metastatic bone pain.Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.Management of skeletal metastases: An orthopaedic surgeon's guideBone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesDoxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.Selenium-Substituted Hydroxyapatite/Biodegradable Polymer/Pamidronate Combined Scaffold for the Therapy of Bone Tumour.Perspectives on treatment of metastatic castration-resistant prostate cancer.A new emergency in oncology: Bone metastases in breast cancer patients (Review)Sclerostin: a possible target for the management of cancer-induced bone disease.Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications.Radium-223 for the treatment of prostate cancer.The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.Hypernociceptive responses following the intratibial inoculation of RM1 prostate cancer cells in mice.The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.Pamidronate disodium for palliative therapy of feline bone-invasive tumors.Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?Aluminum Trichloride Inhibits the Rat Osteoblasts Mineralization In Vitro.New Considerations in the Design of Clinical Trials for Bone Metastases.Engineered Multifunctional Nanomedicine for Simultaneous Stereotactic Chemotherapy and Inhibited Osteolysis in an Orthotopic Model of Bone Metastasis.Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.Breast cancer bone metastases: denosumab or zoledronic acid?
P2860
Q27693653-C6521B98-232F-43FD-A6B0-166B41359C71Q30684593-CEAA45BF-657D-4704-9FF6-39A3E5C1695BQ33628466-3CB223FA-FE07-4B59-AAD3-69EEAE30A5FCQ33837316-5D27FFBE-CDE1-4037-AE9F-848C485A9C3CQ34182919-4C479E53-546F-482D-8EB7-331A4AD0F5D9Q34304585-9C244203-8E77-440E-8AA6-D332FF7B4FCBQ34458440-D6DB7E32-715A-4983-8687-1CBFAAB67809Q35750641-8859F9DC-CF0B-4D0B-8A08-97AA581DFA68Q36106734-0172A20E-37B6-4CBA-A25C-1F19F1B25135Q36184214-0C097E07-0546-42C5-A7DF-200901D8BB48Q36871685-CB385C6D-2957-4982-8B51-CC45398C2A9DQ37211824-75C3742B-8047-45D1-8542-A5D2097EA7DEQ38023902-85FC3387-ACAE-4AEC-A8F4-601B80A86710Q38053396-5A6847D2-0C4D-44A4-A06A-D06C570E7EE9Q38073823-1CB28B3A-C608-44D7-A2EE-8F27BD80DE83Q38921712-D53D20DF-A75F-45AE-A38A-576CCFC9ADD6Q38952610-482CEABB-47E2-4D1A-9934-4C57F3380602Q41053000-4C95B165-1773-467D-92AB-760DCC63D593Q41239033-4B38241C-F49D-417A-8F9F-D96B22824CADQ41521414-ED000FEB-BFC8-409E-AB50-DF7389752CB0Q46277675-9892F382-956A-4AC1-B7D3-08C4D925082CQ47139295-19EBA825-1E09-4AD8-AAEF-189C920F8CE8Q48333845-8F6E5084-54F7-47B1-B630-A85B93876B76Q54564134-17D50FDF-E462-4AC0-917F-380F5C58C062Q58217182-7EE77F20-CA50-43AC-BDF9-BBA81BE71628
P2860
Implications of bone metastases and the benefits of bone-targeted therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Implications of bone metastases and the benefits of bone-targeted therapy.
@ast
Implications of bone metastases and the benefits of bone-targeted therapy.
@en
Implications of bone metastases and the benefits of bone-targeted therapy.
@nl
type
label
Implications of bone metastases and the benefits of bone-targeted therapy.
@ast
Implications of bone metastases and the benefits of bone-targeted therapy.
@en
Implications of bone metastases and the benefits of bone-targeted therapy.
@nl
prefLabel
Implications of bone metastases and the benefits of bone-targeted therapy.
@ast
Implications of bone metastases and the benefits of bone-targeted therapy.
@en
Implications of bone metastases and the benefits of bone-targeted therapy.
@nl
P1433
P1476
Implications of bone metastases and the benefits of bone-targeted therapy.
@en
P2093
Allan Lipton
P304
P356
10.1053/J.SEMINONCOL.2010.10.002
P478
37 Suppl 2
P577
2010-10-01T00:00:00Z